TY - JOUR
T1 - Dissecting the mechanisms of linezolid resistance in a drosophila melanogaster infection model of staphylococcus aureus
AU - Diaz, Lorena
AU - Kontoyiannis, Dimitrios P.
AU - Panesso, Diana
AU - Albert, Nathaniel D.
AU - Singh, Kavindra V.
AU - Tran, Truc T.
AU - Munita, Jose M.
AU - Murray, Barbara E.
AU - Arias, Cesar A.
N1 - Funding Information:
Potential conflicts of interest. Dr Arias has received lecture fees, research support, and consulting fees from Pfizer, consulting fees from Cubist, and research support from Astellas, Theravance, and Forest Pharmaceuticals, and he has served as a speaker for Pfizer Novartis, Forest Pharmaceuticals and Cubist. Dr Murray receives grant support from Astellas, Theravance, Forest Pharmaceuticals, and Cubist, and he has served as consultant for Astellas, Theravance, Cubist, Targanta Therapeutics Corporation, Pfizer, Rib-X, AstraZeneca, and Durata Therapeutics. Dr Singh has received research support from Cubist, Astellas, Theravance, and Forest Pharmaceuticals. Dr Kontoyiannis received research support from Merck, Pfizer, and As-tellas, and he has served as a speaker for Gilead and as a consultant for Merck. All other authors report no potential conflicts.
Funding Information:
Financial support. This work was supported in part by Pfizer (an Investigator Initiated Research grant); the National Institute of Allergy and Infectious Diseases, National Institutes of Health (grant R01-AI093749 to C. A. A.); the Instituto Colombiano para el Desarrollo de la Ciencia y Tecnología, Francisco José de Caldas, COLCIENCIAS (graduate scholarship to L. D.); the American Society of Microbiology (Latin American Fellowship for Epidemiology to L. D.); and the Universidad El Bosque (graduate fellowship to L. D.).
PY - 2013/7/1
Y1 - 2013/7/1
N2 - Background. Mini-host models are simple experimental systems to study host-pathogen interactions. We adapted a Drosophila melanogaster infection model to evaluate the in vivo effect of different mechanisms of linezolid (LNZ) resistance in Staphylococcus aureus.Methods. Fly survival was evaluated after infection with LNZ-resistant S. aureus strains NRS119 (which has mutations in 23S ribosomal RNA [rRNA]), CM-05 and 004-737X (which carry cfr), LNZ-susceptible derivatives of CM-05 and 004-737X (which lack cfr), and ATCC 29213 (an LNZ-susceptible control). Flies were then fed food mixed with LNZ (concentration, 15-500 g/mL). Results were compared to those in mouse peritonitis, using LNZ via oral gavage at 80 and 120 mg/kg every 12 hours.Results. LNZ at 500 g/mL in fly food protected against all strains, while concentrations of 15-250 g/mL failed to protect against NRS119 (survival, 1.6%-20%). An in vivo effect of cfr was only detected at concentrations of 30 and 15 g/mL. In the mouse peritonitis model, LNZ (at doses that mimic human pharmacokinetics) protected mice from challenge with the cfr+ 004-737X strain but was ineffective against the NRS119 strain, which carried 23S rRNA mutations.Conclusions. The fly model offers promising advantages to dissect the in vivo effect of LNZ resistance in S. aureus, and findings from this model appear to be concordant with those from the mouse peritonitis model.
AB - Background. Mini-host models are simple experimental systems to study host-pathogen interactions. We adapted a Drosophila melanogaster infection model to evaluate the in vivo effect of different mechanisms of linezolid (LNZ) resistance in Staphylococcus aureus.Methods. Fly survival was evaluated after infection with LNZ-resistant S. aureus strains NRS119 (which has mutations in 23S ribosomal RNA [rRNA]), CM-05 and 004-737X (which carry cfr), LNZ-susceptible derivatives of CM-05 and 004-737X (which lack cfr), and ATCC 29213 (an LNZ-susceptible control). Flies were then fed food mixed with LNZ (concentration, 15-500 g/mL). Results were compared to those in mouse peritonitis, using LNZ via oral gavage at 80 and 120 mg/kg every 12 hours.Results. LNZ at 500 g/mL in fly food protected against all strains, while concentrations of 15-250 g/mL failed to protect against NRS119 (survival, 1.6%-20%). An in vivo effect of cfr was only detected at concentrations of 30 and 15 g/mL. In the mouse peritonitis model, LNZ (at doses that mimic human pharmacokinetics) protected mice from challenge with the cfr+ 004-737X strain but was ineffective against the NRS119 strain, which carried 23S rRNA mutations.Conclusions. The fly model offers promising advantages to dissect the in vivo effect of LNZ resistance in S. aureus, and findings from this model appear to be concordant with those from the mouse peritonitis model.
KW - Drosophila melanogaster
KW - Staphylococcus aureus
KW - cfr
KW - linezolid
KW - resistance
UR - http://www.scopus.com/inward/record.url?scp=84878612475&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878612475&partnerID=8YFLogxK
U2 - 10.1093/infdis/jit138
DO - 10.1093/infdis/jit138
M3 - Article
C2 - 23547139
AN - SCOPUS:84878612475
SN - 0022-1899
VL - 208
SP - 83
EP - 91
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 1
ER -